HARCP

HEROIN ADDICTION AND
RELATED CLINICAL PROBLEMS

The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by volume Browse by article Published Ahead
of Print
 

Heroin Addiction and Related Clinical Problems: 2021, 23, N4 (pages: 43 - 50)

Naltrexone Implant Use in Opioid Use Disorder; an example from Turkey

Demir B., and Altindag A.

Summary: Background: It is known that substance abuse is a growing problem all over the world. Among these substances, heroin stands out with its addiction potential, the physical and mental disorders it causes, and its social effects. Methods: A total of 100 patients admitted to Gaziantep 25 Aralık State Hospital AMATEM Clinic for naltrexone implant application with the diagnosis of Opioid Use Disorder (OUD) between 01.01.2019 and 31.12.2019 were included in the study. The analyses were made with the help of the SPSS 22.0 Program. A p<0.05 level was taken as the threshold level for significance. Results: In terms of clinical statistics, 14.4% of the patients who had been admitted to hospitals in 2019 had made an Extended-Release Naltrexone Implant (ERNI) application. In the evaluation of participating patients at the moment of discharge, 64 (64%) were found to have been discharged with improvement; 11 (11%) were discharged with penalty scores, and 25 (25%) discontinued treatment due to their personal decision. When the first post-ERNI 3-month follow-up examinations of the patients whose data were accessed from the hospital information system were evaluated, 25 patients (40.3%) came to the follow-up examinations. In these examinations, it was found that 7 patients had negative urine toxic screening results for the UTS test. Conclusions: Our study recommends that the eligibility of patients must be carefully assessed in terms of their ERNI application, and that the frequency of clinical follow-ups must be adjusted according to the requirements of each patient. Prospective randomized-controlled trials are needed in our country on ERNI, which is a great hope in terms of treatments designed to avoid the recurrence of OUD.

 

AU-CNS Associazione per l’Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali
Association for the Application of Neuroscientific Knowledge to Social Aims
Via XX Settembre, 83 – 55045 PIETRASANTA (Lucca) - Italy
P. IVA 01681650469 – Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org
Start of page